Cohen Milstein Investigates Claims On Behalf Of Profound Medical Corp. (PROF) Investors
Profound Medical Corp (NASDAQ:PROF) is under investigation by Cohen Milstein Sellers & Toll LLP following significant accounting irregularities. The company, which develops ablation therapies for diseased tissue, disclosed on March 6, 2025, that its Audit Committee discovered a revenue overstatement of $472,000 in Q1 2024.
As a result, Profound's financial statements for the first three quarters of 2024 will require restatement and reissuance. The market reacted negatively to this news, with PROF shares declining 5.9% to close at $6.86 per share on March 7, 2025.
Profound Medical Corp (NASDAQ:PROF) è sotto indagine da parte di Cohen Milstein Sellers & Toll LLP a seguito di significative irregolarità contabili. L'azienda, che sviluppa terapie di ablazione per tessuti malati, ha rivelato il 6 marzo 2025 che il suo Comitato di Audit ha scoperto un'esagerazione dei ricavi di $472.000 nel primo trimestre del 2024.
Di conseguenza, i bilanci finanziari di Profound per i primi tre trimestri del 2024 richiederanno una rettifica e una nuova emissione. Il mercato ha reagito negativamente a questa notizia, con le azioni di PROF che sono diminuite del 5,9%, chiudendo a $6,86 per azione il 7 marzo 2025.
Profound Medical Corp (NASDAQ:PROF) está siendo investigada por Cohen Milstein Sellers & Toll LLP tras importantes irregularidades contables. La empresa, que desarrolla terapias de ablación para tejidos enfermos, divulgó el 6 de marzo de 2025 que su Comité de Auditoría descubrió una sobreestimación de ingresos de $472,000 en el primer trimestre de 2024.
Como resultado, los estados financieros de Profound para los primeros tres trimestres de 2024 requerirán una rectificación y una nueva emisión. El mercado reaccionó negativamente a esta noticia, con las acciones de PROF cayendo un 5.9% para cerrar a $6.86 por acción el 7 de marzo de 2025.
Profound Medical Corp (NASDAQ:PROF)는 중대한 회계 불규칙성으로 인해 Cohen Milstein Sellers & Toll LLP의 조사를 받고 있습니다. 질병 조직을 위한 절제 요법을 개발하는 이 회사는 2025년 3월 6일 감사 위원회가 2024년 1분기 동안 $472,000의 수익 과대 계상 사실을 발견했다고 밝혔습니다.
그 결과, Profound의 2024년 첫 세 분기 재무제표는 수정 및 재발행이 필요합니다. 이 소식에 시장은 부정적으로 반응하여 2025년 3월 7일 PROF 주가는 5.9% 하락하여 주당 $6.86로 마감했습니다.
Profound Medical Corp (NASDAQ:PROF) fait l'objet d'une enquête par Cohen Milstein Sellers & Toll LLP suite à des irrégularités comptables significatives. L'entreprise, qui développe des thérapies d'ablation pour les tissus malades, a révélé le 6 mars 2025 que son Comité d'Audit avait découvert une surestimation des revenus de $472,000 au premier trimestre de 2024.
En conséquence, les états financiers de Profound pour les trois premiers trimestres de 2024 devront être retraités et réémis. Le marché a réagi négativement à cette nouvelle, avec une baisse des actions de PROF de 5,9%, clôturant à $6,86 par action le 7 mars 2025.
Profound Medical Corp (NASDAQ:PROF) wird von Cohen Milstein Sellers & Toll LLP aufgrund erheblicher Buchhaltungsunregelmäßigkeiten untersucht. Das Unternehmen, das Ablationstherapien für erkranktes Gewebe entwickelt, gab am 6. März 2025 bekannt, dass sein Prüfungsausschuss eine Umsatzüberbewertung von $472.000 im ersten Quartal 2024 entdeckt hat.
Infolgedessen müssen die Finanzberichte von Profound für die ersten drei Quartale 2024 neu gefasst und erneut veröffentlicht werden. Der Markt reagierte negativ auf diese Nachricht, und die PROF-Aktien fielen um 5,9%, um am 7. März 2025 bei $6,86 pro Aktie zu schließen.
- None.
- Revenue overstatement of $472,000 discovered in Q1 2024
- Required restatement of three quarters of financial statements
- 5.9% stock price decline following announcement
- Potential legal liability from investor claims
WASHINGTON, DC / ACCESS Newswire / March 12, 2025 / Cohen Milstein Sellers & Toll LLP is investigating claims on behalf of investors in Profound Medical Corp. ("Profound") (NASDAQ:PROF). To learn about your legal options, complete our contact form or email Partner Molly Bowen at mbowen@cohenmilstein.com.
BACKGROUND: Profound is a commercial-stage medical device company that develops and markets therapies for the ablation of diseased tissue. On March 6, 2025, Profound announced that the Audit Committee in discussion with Profound's auditors identified an error which overstated revenue by
NEXT STEPS: If you suffered a significant loss on your investment in PROF and are interested in learning more, complete our contact form or email Partner Molly Bowen at mbowen@cohenmilstein.com.
OUR FIRM: With more than 100 attorneys in eight offices, Cohen Milstein is one of the largest plaintiff-side law firms in the U.S., with more than four decades of experience litigating securities fraud cases. We have recovered billions of dollars for investors, including
Prior results do not guarantee a similar outcome. This may be considered Attorney Advertising.
CONTACT INFORMATION:
Molly Bowen, Esq.
Cohen Milstein Sellers & Toll PLLC
SOURCE: Cohen Milstein Sellers & Toll PLLC
View the original press release on ACCESS Newswire
FAQ
What accounting error was discovered in Profound Medical Corp (PROF) financials?
How did PROF stock price react to the accounting irregularities announcement?
Which law firm is investigating Profound Medical Corp (PROF)?
What financial periods will be restated by Profound Medical (PROF)?
